Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03582475
Title Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

prostate neuroendocrine neoplasm

urethra cancer

prostate small cell carcinoma

ureter small cell carcinoma

urinary bladder small cell neuroendocrine carcinoma

Therapies

Etoposide

Carboplatin + Docetaxel + Etoposide + Pembrolizumab

Cisplatin + Etoposide + Pembrolizumab

Pembrolizumab

Carboplatin + Etoposide + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UCLA / Jonsson Comprehensive Cancer Center Recruiting Los Angeles California 90095 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field